Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Do‐Youn Oh et al.|The Lancet Oncology|2023Cited by 614
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100Markus Moehler, Yung‐Jue Bang, Marina Nechaeva et al.|Journal of Clinical Oncology|2020Cited by 222
Randomized phase <scp>II</scp> study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (<scp>STARGATE</scp>)Min‐Hee Ryu, Yoon‐Koo Kang|Cancer Medicine|2022Cited by 20